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Beyond Dr. Frankenstein’s Monster: Human
Germline Editing and the Implications of
Waiting to Regulate
REBECCA RODRIGUEZ1
From the birth of bioethics in the United States to the hindrance of
advancement caused by laws that claim to remove barriers to innovation,
CRISPR and its germline editing abilities simply cannot live up to their full
potential in the United States unless current limitations are lifted and a more
reasonable approach is taken. While scientific acronyms and analogies to
scissors and word processing functions abound in CRISPR-related articles,
many focus on the patent for the technology itself. Few seek to resolve the
discord that abounds in federal regulations of this emerging biotechnology.
This Comment seeks to do just that and advocates for the adoption of the
2017 American Society of Human Genetics position statement as a rational
and research-based approach.
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I.

INTRODUCTION

Legal scholars, politicians, professors, and law students rarely claim
that the law evolves quickly in response to new technology. Science, on the
other hand, moves at breakneck paces that are substantially faster than the
regulatory bodies that govern it. This leaves such governing bodies at a great
disadvantage while many scientists are confined mostly by the ethics imposed upon them by their own profession.2 New technological and scientific
2. See generally World Medical Association General Assembly, WMA Declaration
of Helsinki – Ethical Principles for Medical Research Involving Human Subjects, WORLD
MED. ASS’N (Mar. 19, 2018), https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
[https://perma.cc/G8F6-FKUE]. The World Medical Association (“WMA”) Declaration of
Helsinki provides ethical guidelines and principles for medical research that involves human
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advances in the world of genetic editing are no different. One of the newest
gene-editing innovations–commonly known as CRISPR-Cas93–has far outpaced the legal ties that may bind it.
The idea of changing one’s genetics has been around for decades, in
everything from literature and entertainment to scientific experiments. While
perhaps the most well-known image conjured by the mention of genetic editing, the monster in Mary Shelley’s Frankenstein was created from an inanimate body and brought to life through chemistry and alchemy, so these edits
to the lifeform cannot be considered editing of the genes.4 The repetitive genetic rewrites of the character Rocket in Marvel’s Guardians of the Galaxy5
come much closer to the type of genetic editing that is currently controversial. But it is Aldous Huxley’s science fiction novel Brave New World, which

subjects. First adopted in 1964, the WMA’s global ethical standards are designed for physicians, but are encouraged to be adopted by all involved in human subject medical research.
These standards include an outline of physician duties, aspects of research protocol, and registration requirements. Id.
3. Questions and Answers About CRISPR, BROAD INST., https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/questions-and-answers-about-crispr
[https://perma.cc/WX8S-MCEG]. This technology is sometimes called just CRISPR or is
paired with an enzyme other than Cas9. For the purposes of this Comment, the nomenclature
used will be CRISPR-Cas9. For more information regarding CRISPR, see infra text accompanying notes 45-71.
4. See generally MARY WOLLSTONECRAFT SHELLEY, FRANKENSTEIN, OR, THE
MODERN PROMETHEUS (1818).
5. See generally GUARDIANS OF THE GALAXY (Marvel Studios 2014). Rocket, a
greedy and vengeful talking raccoon who walks on his hind legs, is the result of unauthorized
genetic and cybernetic experiments. Id. When taunted about his background, Rocket states,
“Well I didn’t ask to get made. I didn’t ask to be torn apart and put back together over and
over and turned into some, some little monster.” Id. at 54:07. Human germline editing critics
share ethical concerns similar to this statement because germline editing is completed before
a child is born – therefore the child cannot give consent to the procedure and must rely on its
parents to make a choice in its best interest – and that genome edit is passed down to the next
generation. See Genome Editing: What are the Ethical Concerns About Genome Editing?,
NAT’L HUM. GENOME RES. INST. (Aug. 3, 2017), https://www.genome.gov/27569225/whatare-the-ethical-concerns-about-genome-editing/ [https://perma.cc/S4L6-G5B8]. For a discussion on germline editing, see infra Part II, Section A. For a discussion on the ethical concerns
posed by scientists regarding germline modification on embryos, see infra Part III, Section
A(2).

588

NORTHERN ILLINOIS UNIVERSITY LAW REVIEW

[Vol. 38-3

addresses a severe form of in vitro eugenics6 in a totalitarian future,7 that
makes the capabilities of science a little less fictional.
While Shelley’s tale of scientific hubris focuses on a scientist consumed
by his creation,8 some in the scientific community view it as an early warning
sign.9 In the name of “improving” society, compulsory sterilization laws
were legal in the state of Virginia until 1974.10 The Supreme Court upheld
such a law in Buck v. Bell in an eight to one decision, justifying sterilizations
of “feeble-minded” women as benefits to the public welfare.11 The theory of
eugenics continued during World War II when German physicians experimented on thousands of nonconsenting concentration camp prisoners.12
The advent of CRISPR-Cas9 brings the fictional and the cruel closer to
reality. Patients on the organ transplant wait lists could receive life-saving
surgery without having to wait years.13 The ability of parents to choose advantageous traits for their unborn child is within reach.14 Genetic diseases
could be eradicated.15 Once-extinct animals could come to life outside a
6. Eugenics is a form of “science that deals with the improvement (as by control of
human mating) of hereditary qualities of a race or breed.” Eugenics, MERRIAM-WEBSTER’S
COLLEGIATE DICTIONARY (11th ed. 2003). The term “eugenics” was coined in 1883 by British
scientist Francis Galton. Galton advocated for rewarding marriages amongst “superior” members of society to promote selective breeding. The work of American eugenicists was later
used by the Nazis in justifying their sterilization programs in the 1930s. See Steven A. Farber,
U.S. Scientists’ Role in the Eugenics Movement (1907-1939): A Contemporary Biologist’s
Perspective, 5 ZEBRAFISH 243, 243-44 (2008).
7. See generally ALDOUS HUXLEY, BRAVE NEW WORLD (1932).
8. See generally SHELLEY, supra note 4.
9. See Kai Kupferschmidt, The Long Shadow of Frankenstein, SCIENCE, Jan. 12,
2018, at 147.
10. See Matthew Wills, When Forced Sterilization was Legal in the U.S., JSTOR
DAILY (Aug. 3, 2017), https://daily.jstor.org/when-forced-sterilization-was-legal-in-the-u-s/
[https://perma.cc/M36A-JC8S].
11. See Buck v. Bell, 274 U.S. 200, 207 (1927) (“Three generations of imbeciles are
enough.”). This decision bolstered the American eugenics movement, which was led in Virginia by Dr. Albert Priddy and Harry Laughlin. See Michelle Oberman, Thirteen Ways of Look
at Buck v. Bell: Thoughts Occasioned by Paul Lombardo’s “Three Generations, No Imbeciles.” 59 J. LEGAL EDUC. 357, 359-60 (2010).
12. United States Holocaust Memorial Museum, Nazi Medical Experiments,
HOLOCAUST
ENCYCLOPEDIA,
https://www.ushmm.org/wlc/en/article.php?ModuleId=10005168 [https://perma.cc/J9MD-N3TU]. One goal of the experiments was to advance
the “master race” through sterilization of many Jews, Roma, and other “undesirable” groups.
This racist ideology involving eugenics was not new, but the Nazis brought it to the forefront.
Id.
13. See discussion infra Part I, Section D.
14. See Paul Knoepfler, The Ethical Dilemma of Designer Babies, TED (Oct. 2015),
https://www.ted.com/talks/paul_knoepfler_the_ethical_dilemma_of_designer_babies/details
[https://perma.cc/262U-AGN7].
15. See generally Heidi Ledford, CRISPR Fixes Embryo Error, 548 NATURE 13
(2017); Emily Mullin, Arming Bodies with CRISPR to Fight Huntington’s Disease and ALS,

2018]

BEYOND DR. FRANKENSTEIN’S MONSTER:

589

movie theater.16 The mixed opportunities presented by new technology bring
both advocates and critics.
Although current use of gene-editing technology on human embryos is
sparse, many CRISPR-Cas9 opponents advocate for a total ban on the technology.17 A January 2016 poll done by the partnership of Harvard T.H. Chan
School of Public Health and STAT reported that eighty-three percent of
Americans oppose gene editing that is done only to improve physical or intellectual characteristics, while approximately sixty-three percent oppose genetic edits to fetuses.18 Opposition on this level breaches the pro-life, prochoice debate. Critics are wary of “designer baby” possibilities and fear parents may “prevent or cure” certain physical differences in order to exact social change.19 Other opponents are averse to any human experimentation, regardless of the stage of life.20 At this point in time, the long-term implications
of genome editing technology such as CRISPR-Cas9 are yet to be found and
fuel some of the controversy.21
Legal scholarship is lacking in the area of germline editing. One can
presume that the complex scientific terminology and principles are daunting
to non-scientists in the legislative and legal divisions.22 To date, the Supreme
MIT TECH. REV. (Oct. 5, 2017), https://www.technologyreview.com/s/608967/arming-bodieswith-crispr-to-fight-huntingtons-disease-and-als/ [https://perma.cc/J6UN-CXF7].
16. See Simon Worrall, We Could Resurrect the Woolly Mammoth. Here’s How.,
NAT’L GEOGRAPHIC (July 9, 2017), https://news.nationalgeographic.com/2017/07/woollymammoths-extinction-cloning-genetics/ [https://perma.cc/Z9M4-9BNX] (discussing the possible resurrection of the woolly mammoth and the accompanying ethical concerns).
17. See Sarah Karlin, Gene Editing: The Next Frontier in America’s Abortion Wars,
POLITICO (Feb. 16, 2016, 5:21 AM), https://www.politico.com/story/2016/02/gene-editingabortion-wars-219230 [https://perma.cc/AU6U-UNLE].
18. Id.
19. See Knoepfler, supra note 14.
20. See Karlin, supra note 17.
21. See, e.g., Emily McManus, Scientists are Trying to Use CRISPR to Fix Everything. What’s Wrong with That?, TED (May 5, 2016), https://ideas.ted.com/scientists-are-trying-to-use-crispr-to-fix-everything-whats-wrong-with-that/ [https://perma.cc/26JP-3ZCM];
see also Jennifer Kahn, The CRISPR Quandry, N.Y. TIMES MAG. (Nov. 9, 2015),
https://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html?_r=0
[https://perma.cc/GB7U-224N].
22. Oral arguments in Ass’n for Molecular Pathology v. Myriad Genetics, Inc. are a
prime example of non-scientists in the legal field trying to make sense of these complex scientific principles. See generally Transcript of Oral Argument, Ass’n for Molecular Pathology
v. Myriad Genetics, Inc., 569 U.S. 576 (2013) (No. 12-398), https://www.supremecourt.gov/oral_arguments/argument_transcripts/2012/12-398_h3dj.pdf
[https://perma.cc/LX2A-RFJP] [hereinafter Transcript of Oral Argument]. “Do you -- you’ve
really lost me when you say that it’s nature that does the alteration rather than the scientist. I
mean, whenever a scientist does an alteration, he does it, you know, by some force of nature.”
Id. at 21:14 (Scalia, J.).
“[M]y understanding is that here, what’s involved, obviously through scientific processes, but
we’re not talking about process. Here, what’s involved is snipping. You’ve got the thing there
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Court has been faced with a CRISPR-Cas9 issue only regarding patent issues.23 This Comment focuses on the scientific background of human
germline editing, current regulations, and the need for evolving regulations
for the use of CRISPR-Cas9 in the human medical products arena.
While complicated, it is necessary to explore the rather recent history of
human germline editing and CRISPR-Cas9. Science and biotechnologies
evolve at a sometimes-alarming rate and regulators need to be aware of how
far science has come in such a short time. The sources of current regulations
covering human germline editing are varied. The FDA, USDA, National Institutes of Health, and funding restrictions through tax appropriations bills all
touch on germline editing, but none address it fully or directly. Due to the
lack of direct and relevant law regarding human germline editing and biotechnologies such as CRISPR-Cas9, it is time for change. The American Society of Human Genetics (ASHG) issued a position statement in 2017 that
addressed the lack of regulation and proposed a set of guidelines for regulators to consider.24 This Comment advocates that this statement should be
adopted in full. Section II of this Comment deals with the scientific background of human germline modification, CRISPR-Cas9, and current uses of
gene editing technologies. Section II explores the current regulations in place
for genetic editing and genetically altered products and why they are inadequate. Section III of this Comment discusses the need for evolving regulations and why the suggestions outlined the ASHG’s position statement
should be adopted.
II.

SCIENTIFIC BACKGROUND

A. Human Germline Modification Explained
When the Human Genome Project25 consortium first announced the
publication of a reference genome in 2001, they predicted that this freelyand you snip – snip off the top and you snip off the bottom and there you’ve got it.” Id. at
41:10 (Roberts, C.J.).
“I’m sorry, I still don’t understand what – in what sense it’s different than just snipping along
– along the line.” Id. at 42:23 (Roberts, C.J.).
23. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576
(2013) (holding that isolated DNA segments occurring naturally are not patent eligible, but
cDNA may be patented); In re Schlich, 2017 U.S. Dist. LEXIS 151060 (S.D.N.Y. Sept. 17,
2017) (denial of a discovery request for pending litigation before the European Patent Office
regarding the patent battle for CRISPR/Cas9 biotechnology).
24. Kelly Ormond, et al., Human Germline Genome Editing, 101 AM. J. HUM.
GENETICS 167 (2017) [hereinafter ASHG Statement].
25. The National Institutes of Health (NIH) and Department of Energy, in conjunction with international partners, formed the Human Genome Project in 1990. Their goal was
to sequence all three billion DNA letters – also called base pairs – in the human body in order
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released “Book of Life”26 would aid researchers in identifying and treating
diseases.27 This was a culmination of projects that were launched in the early
1980s, the goal of one being “to locate disease genes of unknown function
based solely on their inheritance patterns.”28 The mapping of the human genome took science one step closer to editing the DNA of many organisms
and is a noble pursuit.29
There are two types of gene editing, somatic30 and germline.31 Edits
done to somatic cells affect only individuals that receive the treatment.32 This
type of gene editing is less controversial because edits are not passed on to
future generations and undergo rigorous evaluation.33 The National Institutes
of Health Common Fund is in the process of developing the Somatic Cell
Genome Editing Program to provide researchers with tools to safely and effectively edit the genomes of human patients.34 Scientists in the United Kingdom used somatic gene therapy in 2015 to help a one-year-old girl, Layla,
fight leukemia.35 The newest technology, CRISPR-Cas9, was not the method
to provide researchers with more information to understand, treat, and prevent genetic diseases. The complete set of a person’s DNA is referred to as their genome. See Fact Sheet:
Human Genome Project, NAT’L INSTS. HEALTH 1 (Oct. 2010), https://report.nih.gov/NIHfactsheets/Pdfs/HumanGenomeProject(NHGRI).pdf [https://perma.cc/6U82-J4YH].
26. All discoveries made and data compiled by the Human Genome Project were
made available free of charge on the Internet. Id.
27. See International Human Genome Sequencing Consortium Publishes Sequence
and Analysis of the Human Genome, NAT’L HUM. GENOME RES. INST. (Feb. 12, 2001),
https://www.genome.gov/10002192/2001-release-first-analysis-of-human-genome/
[https://perma.cc/J2MU-TM54].
28. Int’l Human Genome Sequencing Consortium, Initial Sequencing and Analysis
of the Human Genome, 409 NATURE 860, 862 (2001) [hereinafter Initial Sequencing].
29. See generally id.
30. Somatic cells do not transfer their genome to the next generation. Gene Editing
in Clinical Disease: Scientific, Ethical and Societal Questions, CTR. FOR GENETICS & SOC’Y
(Nov. 14, 2017), https://www.geneticsandsociety.org/internal-content/gene-editing-clinicaldisease-scientific-ethical-and-societal-questions [https://perma.cc/PQM3-J3JX].
31. See discussion infra note 37.
32. Id.
33. Id.
34. See Somatic Cell Genome Editing, NAT’L INSTS. HEALTH OFF. STRATEGIC
COORDINATION
–
COMMON
FUND,
https://commonfund.nih.gov/editing
[https://perma.cc/DH5W-JCCT]. Funding for this program, approximately $190,000,000 over
the next six years, will be awarded through the NIH Common Fund and does include CRISPRCas9 technology. See Alex Philippidis, NIH Commits $190M to Somatic Gene-Editing
Tools/Tech Research, GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Jan. 24, 2018),
https://www.genengnews.com/gen-news-highlights/nih-commits-190m-to-somatic-gene-editing-toolstech-research/81255414 [https://perma.cc/S8L9-LX6H].
35. See Genome Editing, NAT’L HUM. GENOME RES. INST. (Aug. 3, 2017),
https://www.genome.gov/27569222/genome-editing/ [https://perma.cc/CD2K-JKGC]. All
other treatments to fight Layla’s leukemia had failed, so a gene editing method called TALENs
was employed to treat Layla. Researchers had to extract healthy T-cells, a type of immune
cell, from a donor. These healthy cells were then introduced into Layla’s system once the
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employed by the U.K. scientists, but special permission did have to be obtained to edit Layla’s genome and save her life.36
Germline37 editing, even more so than somatic gene editing, is the
source of much controversy.38 This is because these genetic alterations are
passed to future generations.39 The genetic alterations of germline editing target genes in early stage embryos, eggs, or sperm, not human adults.40 These
changes to the genetic make-up affect all cells in the resulting individual and
are therefore inheritable by that individual’s offspring.41 These inheritable
gene edits would create “permanent changes to the human gene pool.”42 For
researchers seeking to remove fatal genetic diseases from the genome,
germline editing is optimal.43 While it prevents scientists from having to repeat somatic gene therapy in each generation, the long-term effects of
germline editing have not been determined.44
B. What Exactly is CRISPR?
As the “building blocks of life,” DNA is stored in all cells of the body,
other than red blood cells.45 When viruses attack cells, they leave behind their
TALEN enzyme had been used to modify Layla’s “genes to protect the new cells from anticancer drugs . . . .” Sara Reardon, Leukaemia Success Heralds Wave of Gene-Editing Therapies, 527 NATURE 146, 146 (2015). For a description of TALENs, see infra note 73.
36. See NAT’L HUMAN GENOME RES. INST., supra note 35.
37. “Germ” in germline refers to egg and sperm cells that join together to form an
embryo. Germline DNA is the source of DNA for all other cells in the body. NCI Dictionary
of Cancer Terms “germline DNA,” NAT’L CANCER INST., https://www.cancer.gov/publications/dictionaries/cancer-terms/def/germline-dna [https://perma.cc/HS2U-3CW2].
38. See Karlin, supra note 17.
39. See CTR. FOR GENETICS & SOC’Y, supra note 30.
40. See ASS’N OF REPROD. HEALTH PROF’LS, HUMAN CLONING AND GENETIC
MODIFICATION: THE BASIC SCIENCE YOU NEED TO KNOW 5, https://www.arhp.org/uploadDocs/cloning.pdf [https://perma.cc/B2WR-B8FN].
41. Id.
42. Nicholas Wade, Scientists Seek Moratorium on Edits to Human Genome That
Could be Inherited, N.Y. TIMES (Dec. 3, 2015), https://www.nytimes.com/2015/12/04/science/crispr-cas9-human-genome-editing-moratorium.html?_r=0
[https://perma.cc/2FLZANXE].
43. See Alice Park, U.S. Scientists Use CRISPR to Fix Genetic Disease in Human
Embryos for the First Time, TIME (Aug. 2, 2017), http://time.com/4882855/crispr-gene-editing-human-embryo/ [https://perma.cc/UGP5-VBLU].
44. See NAT’L HUMAN GENOME RES. INST., supra note 35.
45. See What is DNA?, GENETICS HOME REFERENCE (May 22, 2018),
https://ghr.nlm.nih.gov/primer/basics/dna [https://perma.cc/SV3Y-LZ2J]. Deoxyribonucleic
acid, or DNA, is the storehouse for genetic material. There are four nucleic acid bases that
make up the human genome, labeled A, T, G, and C. These bases pair up to form units. Repetitive elements are prevalent because each cell requires a duplicate of its DNA when it divides. Just as most cells in the human body have the same DNA, approximately ninety-nine
percent of the three billion bases in the human body are the same in all people. Id.
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DNA.46 Researchers in 2005 found that certain kinds of bacteria contain the
ability to create a record of all the viruses they have been exposed to by storing bits of viral DNA within clustered regularly interspersed short palindromic repeats (“CRISPRs”).47 In those bacteria, the CRISPR system is utilized as an immune system that destroys invading viruses.48 This unique ability to remember which viruses it has been exposed to protects not only the
infected cells, but their progeny as well.49
The CRISPR system contains a protein called Cas9 that can “cut” the
DNA’s double helix.50 In the natural world, bacteria use CRISPR to cut up
and fight off viruses.51 Scientists have a different purpose in the lab, but the
principle remains the same.52 After being guided to the target DNA by guide
RNA,53 Cas9 binds to the targeted DNA.54 Once Cas9 is bound to its target,
that gene effectively shuts off when Cas9 cuts through the DNA.55 This double-stranded DNA break created by the Cas9 protein must then be repaired.
In the natural world, DNA breaks in cells are repaired by either piecing together the broken ends of the DNA with a slight change, or a new piece of

46. See Jennifer Doudna, How CRISPR Lets Us Edit Our DNA, TED (Sept. 2015),
https://www.ted.com/talks/jennifer_doudna_we_can_now_edit_our_dna_but_let_s_do_it_wisely [https://perma.cc/KR78PV53].
47. Eileen M. Kane, Human Genome Editing: An Evolving Regulator Climate, 57
JURIMETRICS 301, 303-04 (2017). In combination with specific enzymes, CRISPRs can essentially remove DNA from viruses that attack the bacteria “in a process known as adaptive immunity” and serves as a defense system. Id. at 304.
48. See NAT’L HUM. GENOME RES. INST., supra note 35.
49. See Doudna, supra note 46.
50. CRISPR and Cas9 have been anthropomorphized in many ways (find and replace
in word processing, scissors, etc.), but the most common analogy likens the technology to a
Swiss Army knife. This shows the cutting power of CRISPR-Cas9, but it does not produce a
scalpel-precise cut. It also creates an image of varying instruments for varying tasks, all rolled
into one neat package. See Rebecca Robbins, The Best and Worst Analogies for CRISPR,
Ranked, STAT (Dec. 8, 2017), https://www.statnews.com/2017/12/08/crispr-analogies-ranked/
[https://perma.cc/9VX9-DPMC].
51. Robert Kolker, This Gene-Editing Technology Will Change the World. But Who
Gets the Credit?, BLOOMBERG BUSINESSWEEK (June 29, 2016), https://www.bloomberg.com/features/2016-how-crispr-will-change-the-world/.
52. Id.
53. The job of ribonucleic acid (“RNA”) is to transfer the genetic code needed for the
creation of proteins from the nucleus to the ribosome. RNA is essential to the creation of
proteins. See What is RNA?, RNA SOC’Y, https://www.rnasociety.org/about/what-is-rna/ (last
visited Dec. 14, 2017). The Cas9 RNA combination can be programmed to detect certain DNA
sequences, allowing precise breaks to be made at that site. See Kane, supra note 47, at 304.
Only twenty letters of the guide RNA are used to target the desired DNA sequence. This makes
designing the edits simple and inexpensive. See GENETICS HOME REFERENCE, supra note 45.
54. See BROAD INST., supra note 3.
55. Id.
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DNA is integrated into that break.56 With these planned breaks in a cell’s
DNA, scientists can introduce new DNA, as long as the two ends of it are
homologous57 to those around it. Biologist Ellen Jorgensen describes this
new piece of DNA as a “Trojan horse” because it makes itself appear to belong.58
These capabilities lead to a powerful tool. Like using the find and replace function of a computer program, scientists can program the Cas9bound RNA to seek out a specific sequence of DNA and change it.59 Edits to
the genome are not limited to insertions of new DNA. Deletions of unwanted
sequences and alterations to existing DNA sequences can also be accomplished through use of the CRISPR-Cas9 system.60 Research has shown that
the CRISPR-Cas9 system also works as a genome editing method in eukaryotic cells.61 Because human cells are eukaryotic cells,62 controversy surrounds the use of this recently discovered targeting system.63
CRISPR-Cas9 has brought cost, speed, accuracy, and efficiency improvements to genome editing.64 The CRISPR-Cas9 system can cleave DNA
without being paired with additional enzymes.65 This reduces costs because
synthetic RNA sequences are less expensive to produce than the proteins
needed for systems used prior to CRISPR.66 Individual genes do not have to
56. See ASS’N OF REPROD. HEALTH PROF’LS, supra note 40.
57. Homologous is defined as “having the same relative position, value, or structure”.
Homologous, MERRIAM-WEBSTER’S COLLEGIATE DICTIONARY (11th ed. 2003).
58. See Ellen Jorgensen, What You Need to Know About CRISPR, TED (June 2016),
https://www.ted.com/talks/ellen_jorgensen_what_you_need_to_know_about_crispr
[https://perma.cc/CB57-QSQZ]. Simply put, CRISPR-Cas9 can be used to add desirable traits
and remove undesirable traits with precision. See id.
59. See Kolker, supra note 51.
60. See David Baltimore et al., A Prudent Path Forward for Genomic Engineering
and Germline Gene Modification, 348 SCIENCE 36 (2015).
61. See Kane, supra note 47 at 304. There are two basic types of cells: eukaryotic and
prokaryotic. A eukaryotic cell possesses a clearly defined nucleus. A prokaryote, on the other
hand, has no internal membranes and therefore lacks a distinct nucleus. The more-simple of
the two, prokaryotic cells, have only one circular chromosome where all the cell’s genetic
information is contained. Bacteria are an example of prokaryotic cells. Eukaryotic cells have
much larger DNA systems “contain[ed] in multiple linear chromosomes.” Human cells are
eukaryotic. See Kara Rogers & Robert J. Kadner, Bacteria, ENCYCLOPEDIA BRITANNICA,
https://www.britannica.com/science/bacteria#ref463521 [https://perma.cc/PR5B-7HNW].
62. See Kane, supra note 47, at 304.
63. See, e.g., Knoepfler supra note 14. The involvement of human DNA in biomedical research, thus leading to possible use in human subjects, elicits ethical concerns from scientists and the public alike. Id.
64. See NAT’L HUM. GENOME RES. INST., supra note 35.
65. Id.
66. ZFN kits, sold by life science company Sigma-Aldrich, begin at $13,000 and can
be customized at additional costs. See SIGMA-ALDRICH, https://www.sigmaaldrich.com/catalog/search?term=zfn&interface=All&N=0&mode=match%20partialmax&lang=en&region=US&focus=product [https://perma.cc/A95H-GDRS]. The popular Golden Gate TALEN
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be targeted separately using CRISPR-Cas9, unlike its predecessors.67 Multiple genes can be targeted simultaneously, reducing the amount of time
needed to make the edit.68 CRISPRs have the ability to be easily matched
with guide RNA.69 Libraries of tens of thousands of guide RNAs have been
created on a genome-scale.70 This creates an ease of use and availability that
older gene-editing technologies could not harness.71
C. CRISPR’s Lackluster Predecessors
Prior technologies, like Zinc-finger nucleases (ZFN)72 and transcription
activator-like effector nucleases (TALENs)73 were complicated and fairly expensive.74 The expansive process ZFN and TALENs required to construct
new proteins was prone to error. CRISPR-Cas9, on the other hand, is simple
and accurate. 75 Editing a gene requires only that a scientist give an “address”
– a short string of letters that delineate a certain location on the gene – to a
kit available from the nonprofit plasmid repository Addgene, costs $425, but is not a complete
system and requires the purchase of additional components. See Golden Gate TALEN and TAL
Effector Kit 2.0, ADDGENE, http://www.addgene.org/taleffector/goldengatev2/#kit-details
[https://perma.cc/6SNC-6BBK]. The materials for CRISPR experiments, on the other hand,
can be obtained for hundreds, not thousands of dollars. See Jorgensen, supra note 58. Outside
the laboratory, gene therapy costs are far from affordable for the average American, with treatments ranging from $373,000 for more common diseases to $1,000,000 for diseases with
fewer eligible patients. See Emily Mullin, Tracking the Cost of Gene Therapy, MIT TECH.
REV. (Oct. 24, 2017), https://www.technologyreview.com/s/609197/tracking-the-cost-ofgene-therapy/ [https://perma.cc/CN9Z-VQVZ].
67. See BROAD INST., supra note 3.
68. Id. CRISPR-Cas9 is a more precise system than its predecessors, meaning that
fewer trials are necessary to achieve the desired results. This reduces time and costs. See NAT’L
HUM. GENOME RES. INST., supra note 35.
69. Id.
70. Silvana Konermann et al., Genome-Scale Transcriptional Activation by an Engineered CRISPR-Cas9 Complex, 517 NATURE 583, 586 (2015). The National Cancer Institute
is one research body that has created a library of small-guide RNAs (sgRNAs). These sgRNAs
“guide the Cas9 enzyme” and allow scientists to quickly and efficiently conduct large-scale
screening of cancer cells. CRISPR’s precision accuracy allows total elimination of the target
gene. See NAT’L CANCER INST., infra note 96.
71. See NAT’L HUM. GENOME RES. INST., supra note 35.
72. ZFN were used by researchers in the 1990s in an attempt to improve the preciseness of gene editing. It is time-consuming and difficult to design and create successful ZFNs
from naturally-occurring proteins. See NAT’L HUM. GENOME RES. INST., supra note 35.
73. These proteins began to be used in genome editing in 2009. TALENs work similarly to ZFNs regarding efficiency of the genetic edits, but engineering TALENs is more simple than synthesizing ZFNs. See id.
74. See price discussion infra note 66.
75. See NAT’L HUM. GENOME RES. INST., supra note 35. One study showed that the
CRISPR’s accuracy for targeted gene mutations is six times more efficient than the results
from ZFN or TALENs. Id.
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strand of guide RNA.76 One scientist claimed that a graduate student could
master the process in an hour and an edited gene could be produced in a couple days.77 Even reasonably priced do-it-yourself kits are available to the general public, who can conduct genetic experiments at home to insert jellyfish
DNA into yeast to make it fluoresce.78
D. Current Uses of Gene Editing Technology
1. GMOs are in the News and on Our Tables
Genetically modified crops and the food derived from them have been
on the market in the United States for years.79 The first commercial crop altered using CRISPR-Cas9 technology, a “waxy” corn variety by DuPont Pioneer, will be on the market around 2020.80 Scientists must no longer wait
years for the desirable traits to be developed in productive plants.81 The
CRISPR-Cas9 system can quickly, and precisely, add or remove genetic
traits in plants.82 In the case of DuPont Pioneer’s waxy corn variety, there
was no need to introduce foreign DNA into the plant because CRISPR-Cas9
was used to partially knock out the gene that creates an undesirable enzyme.83
Researchers continue to explore the use of CRISPR-Cas9 for commercial
crop usage.84 A team at North Carolina State University is investigating ways
to use genome editing to increase oil production in canola.85 One experiment
involved placing a tomato gene into an oilseed plant.86 In two years, not the
76. See BROAD INST., supra note 3.
77. Jennifer Kahn, The CRISPR Quandary, N.Y. TIMES MAG. (Nov. 9, 2015),
https://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html?_r=0
[https://perma.cc/GB7U-224N].
78. See, e.g., Genetic Engineering Kit: Genetically Engineer Any Brewing or Baking
Yeast to Fluoresce, ODIN, http://www.the-odin.com/ge-yeast/ [https://perma.cc/QX3HH2ZM] (offering a starter CRISPR kit for $159 that allows users to insert a fluorescent gene
from a jellyfish into yeast to make the yeast fluoresce).
79. In 1994, the FLAVR SAVR tomato, first genetically-modified food available in
the United States, made its way into the marketplace. See Paul Enriquez, CRISPR GMOs, 18
N.C. J. L. & TECH. 432, 457 (2017).
80. Melody M. Bomgardner, A New Toolbox for Better Crops, CHEMICAL &
ENGINEERING NEWS, June 12, 2017, at 30, 31.
81. Id. at 31-32. DuPont Pioneer’s new waxy corn development began in 2015. This
development to market time span is only five years, as compared to the usual eight years. Id.
82. Id. at 31.
83. Id.
84. See, e.g., Leena Arora & Alka Narula, Gene Editing and Crop Improvement Using CRISPR-Cas9 System, FRONTIERS PLANT SCI., Nov. 2017, at 10. Corn is not the only commercial crop on which researchers are using the CRISPR-Cas9 system. Apples, oranges,
mushrooms, and potatoes have also made the CRISPR research list. Id.
85. See Bomgardner, supra note 80, at 32.
86. Id.
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usual ten-year turnaround with the older techniques, the yield doubled.87 The
team hopes to find and use genes native to the oilseed plant that will produce
the same effect.88
2. Porcine Organs Made Transplant Friendly
CRISPR-Cas9 has been used by geneticists George Church and Luhan
Yang at Harvard University to create gene-edited piglets with organs that are
transplant-friendly to humans.89 Without modification, pig organs are suited
for transplant into humans because of their relative size similarity to human
organs.90 The idea that transplants could eventually be done using pig organs
came about in the 1990s, but it was not until the advent of CRISPR-Cas9 that
such a dream became reality. 91
The need for gene editing arises because the pig genome contains fragments of porcine endogenous retroviruses, known by the acronym PERV,
which could later infect a human transplant recipient.92 To ensure the human
body would not reject the pig organs, it was necessary to remove all traces of
PERV genes from the pig genome.93 In 2016, there were 116,800 patients on
organ transplant waiting lists. 94 The availability of porcine organs for transplant could save thousands of lives.95
3. Cancer Research
CRISPR technology is being used by the National Cancer Institute’s
Laboratory of Cancer and Biology and Genetics to study cancer cells and
how those “mutated genes form abnormal regulatory networks within the
cells.”96 These regulatory networks can serve as targets for new cancer drugs.
87. Id.
88. Id.
89. See Kelly Servick, CRISPR Slices Virus Genes Out of Pigs, But Will It Make Organ Transplants to Humans Safer?, SCI. MAG. (Aug. 10, 2017, 2:00 PM), http://www.sciencemag.org/news/2017/08/crispr-slices-virus-genes-out-pigs-will-it-make-organ-transplants-humans-safer [https://perma.cc/X7BT-QE24].
90. Id.
91. See Gina Kolata, Gene Editing Spurs Hope for Transplanting Pig Organs into
Humans, N.Y. TIMES (Aug. 11, 2017), https://www.nytimes.com/2017/08/10/health/gene-editing-pigs-organ-transplants.html [https://perma.cc/D5J7-69RH].
92. See Servick, supra note 89.
93. Id.
94. See Kolata, supra note 91.
95. Porcine organs could be used to close the large gap between the available number
of human organs and the need. See generally id.
96. CRISPR: Genome Editing Comes of Age, NAT’L CANCER INST. (Sept. 23, 2015),
https://www.cancer.gov/about-cancer/causes-prevention/research/crispr [perma.cc/5NNCQBM9].
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CRISPR’s precision allows the insertion of specific mutations so scientists
can determine what number and order of mutations are necessary to change
a normal cell into a cancer cell.97 These CRISPR-aided studies, currently limited to the laboratory, help scientists understand the evolution of various cancers and can lead to possible treatment approaches.98
4. Three-Parent Children
The greatest controversy with CRISPR involves using this biotechnology to modify human embryos.99 CRISPR-Cas9 technology was not harnessed until 2012,100 but germline genetic modification was successful in human reproduction in 1997.101 Emma Ott, now a thriving 20-year-old, was
born after use of a controversial in vitro fertilization technique called cytoplasmic transfer.102 This technique mixes genes belonging to three people,
thus leaving the resulting children with inherited DNA from three sources.103
Effectually, cytoplasmic transfer resulted in germline modification because
the DNA from both female donors is inheritable through the maternal line.104
While Emma is still young, there have been no recorded complications from
this sort of genetic editing.105

97. Id.
98. Id.
99. See Knoepfler, supra note 14.
100. See Kolker, supra note 51.
101. Steve Connor, Three-Parent Babies: ‘As Long as She’s Healthy, I Don’t Care,’
Says Mother of IVF Child, INDEPENDENT (Aug. 25, 2014, 8:07 PM), http://www.independent.co.uk/news/science/three-child-babies-the-mothers-view-as-long-as-she-s-healthy-i-dont-care-9690059.html [https://perma.cc/7ALB-YWJE].
102. Id. Cytoplasmic transfer involves taking “a small quantity of cytoplasm – the
jelly-like material outside the cell nucleus – from a healthy donor egg [and] inject[ing] [it] into
an egg cell of [Emma’s] mother before being fertilized in vitro with [Emma’s father’s] sperm.”
This type of transfer was used “as a way of boosting the chances of a successful IVF cycle.”
The resulting embryo inherited mitochondrial DNA of the cytoplasm donor, mitochondrial
DNA and nuclear DNA from the mother, and nuclear DNA from the father. Emma was one
of seventeen babies born after successful cytoplasmic transfer. Id.
103. Sara Reardon, Baby’s DNA Mix Revealed, 544 NATURE 17, 17 (2017) (discussing
a more recent cytoplasmic transfer at a U.S. fertility clinic.).
104. Connor, supra note 101. The IVF laboratory where the cytoplasmic transfer took
place was in Britain, where it was illegal to perform human germline modifications. In 2014,
seventeen years after Emma’s birth, the Department of Health in Great Britain ruled that mitochondrial donation does not qualify as genetic modification, even though this germline therapy has inheritable consequences. Id.
105. Id.
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5. Non-Viable Genome Edits Abroad and at Home
In 2015, scientists in China were the first to edit human embryo genomes.106 The CRISPR-Cas9 technology was used on ‘non-viable’ embryos107 from nearby fertility clinics. These embryos were fertilized, but had
an extra set of chromosomes that prevented development beyond the first
stages.108 The focus of the genome edits was the gene responsible for an often-fatal blood disorder, β-thalassemia.109 Forty-eight hours after injecting
eighty-six embryos with the CRISPR-Cas9 complex, seventy-one survived
the procedure and fifty-four were subject to genetic testing.110 The target for
successful slicing of replacement genetic material was close to 100%, but
this experiment yielded a mere fraction of that.111 This led to a suspension of
the research because scientists concluded the technique was “too immature.”112
The following year, another China-based research team reported using
CRISPR-Cas9 editing to edit human embryos in an attempt to make them
HIV-resistant.113 A mutation that alters the CCR5 protein114 was introduced
into the non-viable embryos.115 Approximately fifteen percent of the embryos
were modified successfully.116 This emphasizes the fact that technical difficulties still plague these experiments.117

106. David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human
Embryos, NATURE (Apr. 22, 2015), https://www.nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378 [https://perma.cc/LN45-S97Z].
107. Non-viable embryos cannot result in a live birth. Id.
108. Id.
109. Id.
110. Id.
111. David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human
Embryos, NATURE (Apr. 22, 2015), https://www.nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378 [https://perma.cc/LN45-S97Z]. Only fifty-two percent of the embryos were efficiently cleaved using CRISPR-Cas9 and of those, only 14.3%
were clearly edited in the manner the scientists intended. See Puping Liang, et al.,
CRISPR/Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN & CELL
363, 366 (2015).
112. Cyranoski & Reardon, supra note 106.
113. Ewen Callaway, Second Chinese Team Reports Gene Editing in Human Embryos,
NATURE (Apr. 8, 2016), https://www.nature.com/news/second-chinese-team-reports-gene-editing-in-human-embryos-1.19718 [https://perma.cc/RCN9-ZH8Y].
114. This mutation (known as CCR5Δ32) is carried naturally by some humans. These
people are resistant to the HIV virus because the mutation prevents the HIV virus from infecting the host’s T cells through an alteration of the CCR5 protein. Id.
115. Id.
116. Id.
117. Such low percentages of successful genetic modifications on human embryos are
far from the desired 100% target. See Cyranoski & Reardon, supra note 106.
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China is not the only nation to edit the genes of human embryos. An
international team of scientists at Oregon Health & Science University confirmed, at the end of July 2017, that they used non-viable embryos to target
a gene mutation that causes hypertrophic cardiomyopathy.118 This dominant
mutation, in a gene referred to as MYBPC3, only requires one copy of the
mutated gene to be inherited for a child to be effected.119 The targeting efficiency in this study was much higher than the Chinese experiments with
72.2% efficiency.120 There were fewer undesirable off-target gene mutations
in this study,121 which had been a major concern in previous studies.122
E. Public Reactions to Advances in Biotechnology
There have been mixed reactions to the wide-spread use of CRISPRCas9 technology to edit genes.123 While minimal research has been done to
ascertain the general public’s attitude toward genetic editing, a STATHarvard survey conducted in 2016 intimated that only thirty-five percent of
citizens in the United States would support therapeutic genetic treatment for
unborn human babies.124 A more systematic study was done later that year
that contradicted the findings of the previous study.125 Gene therapies, both
somatic and germline, were seen as acceptable by approximately two-thirds
of respondents, with over half of them expressing support for treating medical conditions with genetic editing.126 Genetic enhancements did not fare as
well, with fifty-one percent of participants finding germline enhancements
unacceptable and thirty-five percent deeming somatic enhancements
118. Heidi Ledford, CRISPR Fixes Disease Gene in Viable Human Embryos, 548
NATURE 13 (Oct. 3 2017), https://www.nature.com/news/crispr-fixes-disease-gene-in-viablehuman-embryos-1.22382 [https://perma.cc/5YDS-A2HA]. Hypertrophic cardiomyopathy involves the thickening of the heart muscle and is “the leading cause of sudden death in young
athletes.” Id. It is notable that this study was privately funded and thus escaped the funding
compliance dilemma that plagues federally funded institutions. See funding discussion infra
pp. 25-26.
119. Id.
120. Hong Ma, et al., Correction of a Pathogenic Gene Mutation in Human Embryos,
548 NATURE 413, 415 (2017).
121. Id. at 416-17.
122. See Cyranoski & Reardon, supra note 106, see also Callaway, supra note 113.
123. See, e.g., Knoepfler supra note 14 (advocating for a complete ban on human genetic modification). But see STEVE OLSON & COMMITTEE ON SCIENCE, TECHNOLOGY, AND LAW
POLICY AND GLOBAL AFFAIRS, INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: A GLOBAL
DISCUSSION 7 (2015) [hereinafter SUMMIT] (calling for regular review of advances in clinical
germline editing to determine when it should proceed under regulatory oversight).
124. See Dietram A. Scheufele, et al., U.S. Attitudes on Human Genome Editing, 357
SCIENCE 553, 553 (2017). The survey did not differentiate between somatic and germline edits.
Id.
125. Id.
126. Id.
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unacceptable. 127 The distinction between genome editing for enhancement
and treatment carried more weight than the distinction between somatic and
germline modifications.128 Finally, an online survey of 2,493 subjects, the
results of which were published in May 2016, showed there was relative support for furthering this type of biotechnology and research, even when the
potential risks were disclosed.129
III.

SCIENTIFIC AND LEGAL REGULATIONS TO DATE

A. Bioethics
The discovery and use of CRISPR has sparked debate throughout the
scientific community regarding the ethical considerations of forever changing not only one person’s genome, but the genetic make-up of all their offspring.130 Long-term effects of human germline modification have yet to be
discovered and many scientists have called for a complete moratorium131–
some call it a “pause”132–on clinical applications of CRISPR technology.133
This “pause” is akin to the 1970s moratorium on molecular cloning.134
1. The Birth of Bioethics in the United States
Prior to the 1970s, science as a profession was fairly self-governing in
determining hierarchical authority and recognition of accomplishments.135
While other professions addressed the changes in the so-called “social contract” between their work and society as the decades have passed, the scientific profession lagged.136 Science has always separated itself from society.137

127.
128.

Id. at 553-54.
Dietram A. Scheufele, et al., U.S. Attitudes on Human Genome Editing, 357
SCIENCE 553, 553 (2017). Religion appears to play a role in the support and/or disapproval of
genome editing and embryonic research. Id. at 554. Much of this discussion about religious
implications is outside the scope of this Comment.
129. Steven M. Weisberg, Daniel Badgio, & Anjan Chatterjee, A CRISPR New World:
Attitudes in the Public Toward Innovations in Human Genetic Modification, 5 FRONTIERS PUB.
HEALTH
1,
7
(May
22,
2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439143/pdf/fpubh-05-00117.pdf. [https://perma.cc/3XSD-E2Q4].
130. See Knoepfler, supra note 14.
131. See Baltimore et al., supra note 60, at 37.
132. See Doudna, supra note 46.
133. See Baltimore et al., supra note 60, at 37.
134. See Doudna, supra note 46.
135. See JUNE GOODFIELD, PLAYING GOD 77-79 (1977).
136. Id. at 79.
137. Id. at 86-87. History had not been kind to scientists who focused solely on facts
and the results of investigations. The technological advances of the Twentieth Century
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This separation and superiority complex was widespread in the eugenics138
research done at Cold Spring Harbor Eugenics Record Office, funded in part
by the renowned Carnegie Institute and the Rockefeller family.139 While eugenics was considered a legitimate science at the time, public sentiment
rightly turned against such research, and discomfort grew with conducting
human scientific research.140
Senator Walter Mondale initiated Senate hearings in the late 1960s regarding the new life science technologies and what mechanisms the government should put in place.141 This was prior to the public disclosure of the
Tuskegee Syphilis Study,142 which, when revealed, led to the creation of the
first bioethics commission.143 The National Commission for the Protection
of Human Subjects of Biomedical and Behavioral Research (National Commission) was created in 1974.144 The most well-known product of this commission is the Belmont Report,145 which paved the way for federal regulations
regarding human subjects in research.146 The framework devised by the

intertwined science and society to a point where governments and the public could no longer
allow science to proceed unchecked. Id.
138. See Eugenics, supra note 6.
139. See Joshua A. Krisch, When Racism was a Science, N.Y. TIMES (Oct. 13, 2014),
https://www.nytimes.com/2014/10/14/science/haunted-files-the-eugenics-record-office-recreates-a-dark-time-in-a-laboratorys-past.html [https://perma.cc/GT4E-GB4U].
140. Id. The ethical concerns brought forward by the Human Genome Project encouraged the creation of an online archive of the Eugenics Records Office files in 2000. Transparency of American scientists improperly using science as a method to hide racist research is
thought to serve as a warning to today’s society. Id.
141. Jenny Dyck Brian & Robert Cook-Deegan, What’s the Use? Disparate Purposes
of U.S. Federal Bioethics Commissions, 47 HASTINGS CTR. REP. S14, S14-16 (2017).
142. For 40 years, researchers, backed by funding from the United States government,
conducted a medical study on economically disadvantaged African American men. They lied
about the purpose of this medical study and denied the participants access to standard treatments for their disease. This non-therapeutic study made no headway to disease cures or prevention in an area that had already been documented by the medical community. See Ruqaiijah
Yearby, Exploitation in Medical Research: The Enduring Legacy of the Tuskegee Syphilis
Study, 67 CASE W. RES. L. REV. 1171, 1172-73 (2017).
143. See Dyck Brian & Cook-Deegan, supra note 141, at S14.
144. Id.
145. NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR
THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH (1978). The Commission was tasked with
identifying ethical principles and developing guidelines for the use of human subjects in biomedical and behavioral research. Id. at 1. The basic ethical principles focused on by the Belmont Report included: (1) respect for persons; (2) beneficence, the consideration of a human
subject’s well-being, broken down into doing no harm and “maximize possible benefits and
minimize possible harms”; and (3) justice. Id. at 4-6.
146. See, e.g., Protection of Human Subjects, 45 C.F.R. §§ 46.101-46.505 (2010).
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National Commission in the 1970s is part of the current debate surrounding
U.S. research policy.147
The first report regarding the prospect of genetic engineering in human
beings, Splicing Life,148 came about in 1982 not as part of a legislative mandate, but in response to concerns from Jewish, Catholic, and Protestant councils about the use of recombinant DNA in gene therapy.149 Prior to this report,
no one federal agency was tasked with oversight or control of genetic engineering techniques.150 The President’s Commission for the Study of Ethical
Problems in Medicine and Biomedical and Behavioral Research found that,
although genetic engineering technology was advancing rapidly, the public
concern about “rema[d]e human beings” was exaggerated.151 The Commission called for thoughtful, close scrutiny for any procedures that might create
germline genetic changes and for those whose aim was to “enhanc[e] normal
people, as opposed to remedying recognized genetic defects.”152
This report also got to the heart of the public uneasiness that is still a
concern today. It is often referred to as the “Frankenstein factor” because the
public fears change to the nature of human beings.153 With the invention of
complicated biotechnology that few members of society understand, the high
level of anxiety surrounding such experimentation is understandable.154 People worry that incurable diseases, even biological weapons, may be created
in laboratories.155
2. Scientists Confer on CRISPR Technology
While some scientists in the 1970s were unsettled by removing genes
from one genome and inserting them into another,156 an international group
of scientists in late 2015 called for a moratorium on making human germline
147.
148.

See Dyck Brian & Cook-Deegan, supra note 141, at S14.
PRESIDENT’S COMM’N FOR THE STUDY OF ETHICAL PROBLEMS IN MED. &
BIOMEDICAL & BEHAVIORAL RESEARCH, SPLICING LIFE: A REPORT ON THE SOCIAL AND
ETHICAL ISSUES OF GENETIC ENGINEERING IN HUMAN BEINGS (1982) [hereinafter President’s
Commission].
149. See Dyck Brian & Cook-Deegan, supra note 141, at S15.
150. See President’s Commission, supra note 148, at 2.
151. Id.
152. Id. at 3.
153. Id. at 14.
154. See Transcript of Oral Argument, supra note 22. Notwithstanding the Justices’
confusion regarding how CRISPR works, one can see how the general public would be wary
of such a complicated addition to the metaphorical technological arsenal.
155. See Eric Niiler, The Pentagon Ponders the Threat of Synthetic Bioweapons,
WIRED (July 10, 2017, 7:00 AM), https://www.wired.com/story/the-pentagon-ponders-thethreat-of-synthetic-bioweapons/ [https://perma.cc/UY4E-HL2E] (discussing the U.S. military’s response to a hypothetical bio-engineered virus).
156. See President’s Commission, supra note 148, at 14.
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modifications.157 This international summit addressed the deficiencies in
CRISPR-Cas9 as well as its possible applications.158
Caution was encouraged to be exercised in abundance by many researchers attending the summit.159 One scientist extoled the goal of society
as “promot[ing] a better life for all, and . . . ensur[ing] that everybody can
live a life in dignity and freedom.”160 The lack of data on future germline
editing implications is a major sticking point.161 More than one scientist at
the summit was reluctant to endorse germline editing due to the unpredictable
risks to future generations.162 With the prediction that the benefits of germline
editing may be outweighed by the unknown long-term harms, there was a
morality call for not only researchers but future parents to take the status of
a human embryo, lacking the capability to make decisions for its own future,
into account.163
The wide-spread introduction of CRISPR-Cas9 technology for editing
the human germline prompted scientists to self-regulate regarding the appropriateness of proceeding with making permanent changes to the human genome.164 As with most issues, the scientific community is still divided on
whether science should be vigorously pursued or if a pause is necessary to
fully comprehend and address the implications of permanently altering the
human genome.165 The end of the International Summit on Human Gene Editing brought the following conclusions: (1) basic and preclinical research
should proceed, but no pregnancies should be established using modified
cells and all research is subject to legal and ethical rules; (2) somatic gene
editing may proceed within current and evolving regulations; (3) proceeding
with germline editing would be “irresponsible” due to unresolved safety issues, lack of societal consensus, and wide-spread regulatory or legislative
bans; and (4) continuation of an international forum to establish norms and
discourage inappropriate activities.166 While these conclusions provide an excellent base for scientists to self-regulate, the Summit’s third conclusion, that

157. See Doudna, supra note 46.
158. See SUMMIT, supra note 123, at 1-2.
159. Id. at 3.
160. Id. at 4.
161. Id.
162. Id.
163. STEVE OLSON & COMMITTEE ON SCIENCE, TECHNOLOGY, AND LAW POLICY AND
GLOBAL AFFAIRS, INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: A GLOBAL DISCUSSION
4 (2015).
164. The academies that convened to seek the moratorium lack regulatory power, but
such a strong declaration of moral authority was likely to be widely accepted by scientists
across the globe. See Doudna, supra note 46.
165. See generally Wade, supra note 42.
166. See SUMMIT, supra note 123, at 6-7.
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proceeding with germline editing would be irresponsible, is too narrow and
focuses only on the fear of failure instead of the promise of success.
B. Federal Regulations
Legislators have grown more aware of the need to regulate emerging
biotechnologies.167 Yet, regulations have always served as the tortoise pitted
against science’s hare with the finish line far in the distance. Relevant regulations are sorely lacking while prohibitions on federal funding for research
involving human embryos is overly strict.168 In order to determine how current regulations should look, one must examine those currently in place and
how they are currently ineffectual.
1. GMOs and CRISPR-Cas9
Genetically modified organisms (GMOs) have been regulated in the
United States since 1986.169 The Food and Drug Administration regulates
human and animal food that is a product of genetically engineered plants.170
Currently, gene-edited crops are not regulated in the same way genetically
engineered crops are.171 Companies that create gene-edited plants and wish
to market them to consumers can ask the USDA whether regulatory review
is required for that product. To date, gene-edited plants lacking foreign DNA

167. See infra notes 169, 177-81 and accompanying text. Possible challenges faced by
regulatory agencies, such as jurisdiction and protecting consumers using risk-analysis tools,
were acknowledged in NAT’L ACADS. OF SCI., ENGINEERING, & MED., PREPARING FOR FUTURE
PRODUCTS OF BIOTECHNOLOGY 11 (2017).
168. See discussion infra Part II, Section B(5) and notes 196-208.
169. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,3302
(June 26, 1986) [hereinafter Coordinated Framework]. Agency jurisdiction over new biotechnologies is determined by the use of the product. Id. at 23,304. See also Luis Acosta, Restrictions on Genetically Modified Organisms: United States, LIBR. CONGRESS (Mar. 2014),
https://www.loc.gov/law/help/restrictions-on-gmos/usa.php [https://perma.cc/2TU9-4WRL]
(describing GMOs in terms of the structure of agencies tasked with regulating them and the
restrictions placed upon research, production, and marketing).
170. See Federal Food, Drug, and Cosmetics Act, 21 U.S.C. §§ 16-2252; see also National Bioengineered Food Disclosure Standard, 7 U.S.C. § 1639 (2016); see also Food from
Genetically Engineered Plants, U.S. FOOD & DRUG ADMIN. (Jan. 4, 2018),
https://www.fda.gov/Food/IngredientsPackagingLabeling/GEPlants/default.htm
[https://perma.cc/PQZ5-5UF7] (providing a brief history of the FDA’s biotechnology policies).
171. See Bomgardner, supra note 80, at 32. PREPARING FOR FUTURE PRODUCTS OF
BIOTECHNOLOGY concluded that as the rate of biotechnology is growing, societal factors will
remain important in the debate regarding the uses of biotechnology products. See NAT’L
ACADS. OF SCI., ENGINEERING, & MED., PREPARING FOR FUTURE PRODUCTS OF
BIOTECHNOLOGY 172-74 (2017).
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are not under the USDA’s regulatory authority.172 Many researchers agree
that the regulatory focus should be on the foreseeable risks posed by added
or altered traits instead of the process used to insert the trait into the plant.173
Using CRISPR-Cas9, Penn State professor Yinong Yang removed a
specific browning enzyme from a mushroom’s DNA in 2016. 174 The USDA
later confirmed that this mushroom would not require USDA approval or
regulatory review.175 This mushroom differs from most GMO crops because
no foreign DNA was ever introduced; only naturally occurring enzyme production was removed.176
2. Early Regulatory Framework for Genetically Altered
Goods
With concerns about “whether the regulatory framework that pertained
to products developed by traditional genetic manipulation techniques was adequate for products obtained with [then] new techniques,”177 a comprehensive Federal regulatory policy was published in 1986.178 Setting forth the system for evaluating modern biotechnology products was based upon laws that
were designed to protect public health and the environment.179
Human genetics research was not addressed until 2004 when the President’s Council on Bioethics180 proposed modifications to legislation
172. See Bomgardner, supra note 80 at 34.
173. Id. One example of a foreseeable risk given by the director of the Center for Science in Public Interest, Gregory Jaffe, would be the possibility of allergic reactions if a Brazil
nut gene that improved resistance to disease were inserted into another plant. Id.
174. See Chuck Gill, Gene-Edited Mushroom Created by Penn State Researcher is
Changing
GMO
Dialogue,
PENN
ST.
NEWS
(Apr.
19,
2016),
http://news.psu.edu/story/405406/2016/04/19/research/gene-edited-mushroom-created-pennstate-researcher-changing-gmo [https://perma.cc/3M66-JZDF].
175. Id.
176. Id.
177. Coordinated Framework, supra note 169, at 23,302.
178. See id. This framework laid out which agencies oversee biotechnology products—mainly the EPA, FDA, and USDA—and was later updated to include descriptions for
“proper basis for agencies’ exercise of oversight authority within the scope of discretion afforded by statute.” EMERGING TECHNOLOGIES INTERAGENCY POLICY COORDINATION COMM.’S
BIOTECHNOLOGY WORKING GRP., NATIONAL STRATEGY FOR MODERNIZING THE REGULATORY
SYSTEM FOR BIOTECHNOLOGY PRODUCTS (2016), https://www.epa.gov/sites/production/files/2016-12/documents/biotech_national_strategy_final.pdf [https://perma.cc/67V96534] [hereinafter STRATEGY].
179. See STRATEGY, supra note 178. Precisely editing the human genome was still in
the future when this framework was adopted, so it focused only on enhanced or manufactured
foods, waste disposal, medicines, and pesticides. See id.
180. Formed by an executive order in 2001 and formed to advise the President on
emerging bioethical issues, the President’s Council on Bioethics was tasked with five functions:
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targeting possibly unethical practices in human reproduction.181 Members of
the Council were acutely aware that public policy as well as public understanding were far behind biotechnical developments. Somatic gene therapy
was addressed at length by the Council, but it was only hypothetical at the
time.182 No products for gene-therapy have been approved for general use by
the FDA and any such products require the “submission of an investigational
new drug (IND) application to the FDA.”183
3. Updated Framework Restricts Progress
Biotechnology advancements, such as CRISPR-Cas9, led to an attempt
to modernize regulations for products created using such technology.184 The
1986 framework set up the regulatory structure, but it was overly complicated
and burdensome for researchers seeking funding and left uncertainty about
each agency’s jurisdiction.185 In acknowledging the rapid advancements in
the biotechnology field, the 2017 Update to the Coordinated Framework for
the Regulation of Biotechnology stresses the safety of biotechnology products, aims to increase public confidence, and strives to remove barriers to
innovation.186 While this update may increase public confidence by simplifying and breaking out what each agency’s roles, responsibilities, and goals
are,187 “unnecessary barriers to future innovation and competitiveness”188 remain. The complete ban on germline therapy, as discussed below, is a restriction on innovation.189
(1) to undertake fundamental inquiry into the human and moral significance of developments
in biomedical and behavioral science and technology;
(2) to explore specific ethical and policy questions related to these developments;
(3) to provide a forum for a national discussion of bioethical issues;
(4) to facilitate a greater understanding of bioethical issues; and
(5) to explore possibilities for useful international collaboration on bioethical issues.
Exec. Order No. 13,237, 66 Fed. Reg. 59,851 (Nov. 30, 2001).
181. PRESIDENT’S COUNCIL ON BIOETHICS, REPRODUCTION & RESPONSIBILITY: THE
REGULATION OF NEW BIOTECHNOLOGIES
xviii
(2004)
https://repository.library.georgetown.edu/bitstream/handle/10822/559381/_pcbe_final_reproduction_and_responsibility.pdf?sequence=1&isAllowed= [https://perma.cc/AW5B-EB7E] [hereinafter
REPRODUCTION & RESPONSIBILITY].
182. Id. at 105-10
183. Id. at 111.
184. See Cyranoski & Reardon, supra note 106.
185. EPA, MODERNIZING THE REGULATORY SYSTEM FOR BIOTECHNOLOGY PRODUCTS:
FINAL VERSION OF THE 2017 UPDATE TO THE COORDINATED FRAMEWORK FOR THE REGULATION
OF BIOTECHNOLOGY 5 (2017), https://www.epa.gov/sites/production/files/201701/documents/2017_coordinated_framework_update.pdf. [https://perma.cc/YYX3-SXR3] [hereinafter FINAL VERSION].
186. Id. at 1.
187. See, e.g., id. at 8-35.
188. Id. at 1.
189. See discussion infra Part III, Section B(5)-(7).

608

NORTHERN ILLINOIS UNIVERSITY LAW REVIEW

[Vol. 38-3

4. The Common Rule Would Apply if Germline Editing Was
Allowed
Research on human subjects is heavily regulated in the United
States.190 Federal Policy for the Protection of Human Subjects, referred to as
the “Common Rule” was adopted in 1991.191 These protections were codified
by fifteen federal agencies and departments in separate regulations, with the
regulations of the Department of Health and Human Services being most applicable to CRISPR-Cas9.192 Under this policy, any research institutions supported by the funding from the federal government must comply with all requirements.193 The Common Rule applies, with a few exceptions, to all research that involves human subjects.194 It outlines the requirements for informed consent, institutional review board involvement and functions, assurances required for the protection of the rights and welfare of the human subjects, certification requirements, and research approval requirements.195
5. Lack of Federal Funding Stymies CRISPR-Cas9 Innovation
Research into human germline modification only partially falls under
the Common Rule.196 While any research done involving human subjects

190. Protection of Human Subjects, 45 C.F.R. §§ 46.101-46.505 (2009); see infra note
194.
191. Id.
192. Basic HHS Policy for Protection of Human Research Subjects, 45 C.F.R. §§
46.101-46.124 (2009).
193. Assuring Compliance with This Policy – Research Conducted or Supported By
Any Federal Department or Agency, 45 C.F.R. § 46.103 (2009). The revised final rule declined to extend the Common Rule to privately-funded clinical trials. Federal Policy for the
Protection of Human Subjects, 82 Fed. Ref. 7149, 7150 (Jan. 19, 2017). Originally set to become effective January 19, 2018, the effective date of the revised Common Rule was extended
to July 19, 2018. HHS and 15 Other Federal Departments and Agencies Announce an Interim
Final Rule that Delays Both the Effective Date and the General Compliance Date of the Revisions to the Federal Policy for the Protection of Human Subjects to July 19, 2018, U.S. DEP’T.
HEALTH & HUM. SERVS. (Jan. 17, 2018), https://www.hhs.gov/ohrp/interim-final-rule-common-rule.html [https://perma.cc/29MZ-BAEA].
194. 45 C.F.R. §46.102(f) (2009) defines “human subject” as “a living individual
about whom an investigator (whether professional or student) conducting research obtains (1)
data through intervention or interactions with the individual, or (2) identifiable private information.” The regulation provides additional protections for pregnant women, fetuses, and
newborns. 45 C.F.R. §§ 46.201-46.207 (2009). Prisoners are provided additional protections
under 45 C.F.R. §§ 46.301-46.306 (2009). There are additional requirements for using children as research subjects. 45 C.F.R. §§ 46.401-46.409 (2009).
195. See generally 45 C.F.R. § 46 (2009).
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must adhere to the requirements of the Common Rule,197 currently, federal
funding for such research is prohibited.198 This prohibition is a result of the
Dickey-Wicker amendment (D-W), which bars the NIH from providing federal funding for the creation of human embryos for research purposes as well
as the destruction, discard, or subjecting human embryos “to risk of injury or
death greater than that allowed for research on fetuses in utero.”199 Each year
since 1996, the D-W has been added to Labor, Health and Human Services,
and Education appropriations legislation.200 After President Obama issued an
executive order in 2009,201 authorizing the NIH to fund and conduct embryonic stem cell research, the United States Court of Appeals for the District of
Columbia affirmed in Sherley v. Sebelius202 that D-W was not violated because the present tense text addressing research is ambiguous and that NIH’s
interpretation of D-W is reasonable.203
Funding has continued to be an issue for researchers seeking federal
funding for germline modification studies.204 Section 749 of the
196. See Rebecca Dresser, Genetic Modification of Preimplantation Embryos: Toward
Adequate Human Research Policies, 82 MILBANK Q. 195 (2004) (discussing shortcomings of
regulations for genetically modified embryos).
197. Id.
198. See, With Stringent Oversight, Heritable Germline Editing Clinical Trials Could
One Day be Permitted for Serious Conditions; Non-Heritable Clinical Trials Should be Limited to Treating or Preventing Disease or Disability at this Time, NAT’L ACAD. MED. (Feb. 14,
2017),
https://nam.edu/with-stringent-oversight-heritable-germline-editing-clinical-trialscould-one-day-be-permitted-for-serious-conditions-non-heritable-clinical-trials-should-belimited-to-treating-or-preventing-diseas/ [https://perma.cc/P446-CX5P].
199. The Balanced Budget Downpayment Act, Pub. L. No. 104-99, § 128, 110 Stat.
34 (1996).
200. 156 CONG. REC. S7036 (daily ed. Sept. 13, 2010) (statement of Sen. Specter).
201. Exec. Order. No. 13,505, 74 Fed. Reg. 10,667 (Mar. 11, 2009) (lifting human
embryonic stem cell research funding restrictions instituted in the Bush administration).
202. Sherley v. Sebelius, 644 F.3d 388, 394-96 (2011); see Chelsea L. Gulinson, Embryonic Stem Cell Tourism, 58 JURIMETRICS 17 (2017) (arguing that restricting stem cell research funding not only impedes scientific progress, but promotes risky procedures conducted
abroad).
203. Sherley v. Sebelius bounced from the District Court to the Court of Appeals multiple times for standing related issues. The final decision rested on the fact that NIH was not
funding research projects that obtained embryonic stem cells by destroying embryos, but provided funding for projects in which embryonic stem cells would be used. Sherley, 644 F.3d.
at 390. Unfortunately, D-W still applies to germline modifications to human embryos due to
the high death/destruction rate of the embryos.
204. When government funds are not available to institutions that rely on federal grants
for most of their research funding, private funding must be obtained. See Tanya Lewis, Congress Just Put a Massive Roadblock in the Way of Genetically Editing Human Embryos, BUS.
INSIDER (Dec. 16, 2015, 2:45 PM) http://www.businessinsider.com/congress-bans-fundingfor-embryo-gene-editing-2015-12 [https://perma.cc/BZ72-PRHF] (discussing the funding
limitations of the Consolidated Appropriations Act of 2016, Pub. L. No. 114-113, § 749, 129
Stat. 2242, 2283 (2015)).
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appropriations bill for fiscal year ending September 30, 2016, states “None
of the funds made available by this Act may be used . . . in research in which
a human embryo is intentionally created or modified to include a heritable
genetic modification.”205 This rider was renewed again for fiscal year
2017.206 This rider essentially continues the ban of therapeutic germline modifications and creates a roadblock for any corporate entity that seeks to gain
FDA approval for clinical trials.207 Limiting funding for human germline editing to privately funded institutions creates a lack of transparency that is required for publicly funded institutions. Withholding funding simply encourages back-alley deals and research. As of the writing of this Comment, a consolidated appropriations bill has not been passed for fiscal year 2018.208
6. Purporting Advancement of Biomedical Research, the
21st Century Cures Act Falls Flat
The end of 2016 brought passage of the 21st Century Cures Act209
(“Cures Act”), legislation designed to accelerate development of biomedical
products and availability of advances to needy patients.210 The Precision
Medicine Initiative outlined in the Cures Act provides funding for disease
prevention as well as diagnosis and treatment.211 Yet, nowhere in this statute
is genetic editing authorized. Precision is one of the advantages touted by
CRISPR supporters,212 but it does not seem to be precise enough to be included in the Precision Medicine Initiative. There is authorization for use of
“targeted drugs for rare diseases,”213 but the qualifications for incorporating
205. Consolidated Appropriations Act of 2016, Pub. L. No. 114-113, § 749, 129 Stat.
2242, 2283 (2015).
206. Consolidated Appropriations Act of 2017, Pub. L. No. 115-31, § 736, 131 Stat.
135, 173 (2017).
207. I. Glenn Cohen & Eli Y. Adashi, The FDA is Prohibited from Going Germline,
353 SCIENCE 545, 546 (2016).
208. Press Release, U.S. House of Representatives Committee on Appropriations,
House Approves Budget and Emergency Supplemental Agreement (Feb. 9, 2018), https://appropriations.house.gov/news/documentsingle.aspx?DocumentID=395097
[https://perma.cc/7JGE-87HK] (approving funding for government operations until March 23,
2018).
209. 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (2016) [hereinafter
Cures Act]. In addition to promoting medical product development and granting new authority
to the FDA for training and retention of experts, major funding was authorized for NIH Innovation Projects, the Precision Medicine Initiative, the “BRAIN Initiative,” adult stem cell research, FDA Innovation Projects, and Opioid Abuse Crisis funding for the States. See id.
210. See id.
211. 21st Century Cures Act, Pub. L. No. 114-255, § 498E(a), 130 Stat. 1033, 1048
(2016).
212. See Kolker, supra note 51.
213. 21st Century Cures Act, Pub. L. No. 114-255, § 529A, 130 Stat. 1033, 1091
(2016).
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genetically targeted technology – much like what CRISPR-Cas9 technology
can offer – are limited to non-replicating nucleic acid and analogous compounds,214 which are not included in the type of gene therapy CRISPR-Cas9
can provide.215 In fact, the word “germline” is not to be found in the entirety
of the Cures Act.
7. Scientific Community Proposes Balance
In February 2017, a committee from the National Academy of Sciences,
Engineering and Medicine endorsed the modification of human embryos
with the limitation that it only be done to correct mutations causing “serious
disease or condition” when no other “reasonable alternatives” are available.216 This caveat is reasonable considering the current practical applications
of this biotechnology and lack of knowledge regarding long-term consequences of human germline modifications.217
The most applicable document to human germline editing using the
CRISPR-Cas9 system is a position statement issued by the American Society
of Human Genetics (ASHG).218 A myriad of professional science organizations from six continents reviewed and endorsed this statement,219 which discussed and offered solutions for the ethical issues raised by CRISPR-Cas9
germline gene editing.220 ASHG’s position is:
(1) At this time, given the nature and number of unanswered
scientific, ethical, and policy questions, it is inappropriate to
perform germline editing that culminates in a human pregnancy. . . .
(2) Currently, there is no reason to prohibit in vitro germline
genome editing on human embryos and gametes, with appropriate oversight and consent from donors, to facilitate research on the possible future clinical applications of gene
214. DNA replication is necessary for cell division and organisms cannot grow without
it. See Richard J. Roberts, Nucleic Acid, ENCYCLOPEDIA BRITANNICA, https://www.britannica.com/science/nucleic-acid/Nucleic-acid-metabolism [https://perma.cc/C2C8-7JD5] (last
visited Feb. 4, 2018).
215. 21st Century Cures Act, Pub. L. No. 114-255, §3012, 130 Stat. 1033, 1091
(2016).
216. Pam Belluck, In Breakthrough, Scientists Edit a Dangerous Mutation from Genes
in Human Embryos, N.Y. TIMES (Aug. 2, 2017), https://www.nytimes.com/2017/08/02/science/gene-editing-human-embryos.html [https://perma.cc/2HHX-MZ2P].
217. See Doudna, supra note 46.
218. See ASHG Statement, supra note 24.
219. Id. at 167.
220. Id. at 169-74.

612

NORTHERN ILLINOIS UNIVERSITY LAW REVIEW

[Vol. 38-3

editing. There should be no prohibition on making public
funds available to support this research. . . .
(3) Future clinical application of human germline genome
editing should not proceed unless, at a minimum, there is (a)
a compelling medical rationale, (b) evidence base that supports its clinical use, (c) an ethical justification, and (d) a
transparent public process to solicit and incorporate stakeholder input.221
This stance is not only rational, but within reach. The ASHG Statement
has mountainous support from highly respected and knowledgeable geneticists around the world.222 Researchers, not limited to private funding, are encouraged by the ASHG Statement to proceed with germline gene editing on
non-viable human embryos that is limited by oversight and consent from donors.223
IV.

NEED TO EVOLVE

The ASHG Statement advocates for waiting on answers to ethical, scientific, and policy questions before editing the germline of viable human embryos; providing public funding for researchers who meet the appropriate
guidelines; and proceeding with human germline editing in future clinical
applications when there is a compelling, evidence-based medical rationale, it
is ethically justified, and the public is aware of the process.224 This statement
should be adopted in full. The following sections discuss how the three suggestions of the ASHG are necessary for United States policy makers to consider.
A. Ethical Considerations Cannot Justify Lack of Forward Movement
The breakneck pace of science cannot be matched by the slow and
steady regulatory system. While scientists and researchers can have multiple
experiments and trials running at the same time for the same principles,
221. Id. at 172-73.
222. Id. at 167. Among those organizations that approved the position statement are
the Association of Genetic Nurses and Counselors, Canadian Association of Genetic Counsellors, International Genetic Epidemiology Society, American Society for Reproductive
Medicine, Asia Pacific Society of Human Genetics, British Society for Genetic Medicine,
Human Genetics Society of Australasia, Professional Society of Genetic Counselors in Asia,
and Southern African Society for Human Genetics. Kelly Ormond, et al., Human Germline
Genome Editing, 101 AM. J. HUM. GENETICS 167 (2017).
223. See ASHG Statement, supra note 24, at 167.
224. Id. at 172-74.
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legislators and regulatory agencies do not have that luxury.225 This does not
excuse the lack of proper regulations and funding for human germline editing. Just as the ASHG proposed, human germline editing research can be
conducted in an ethical manner while complying with all pertinent laws and
policies.226 The benefits of such research and the possibility of medical breakthroughs for those people struggling with devastating genetic diseases far
outweigh the ethical concerns that have been addressed for decades. 227 This
is not a call to immediately begin germline editing on viable human embryos.
As the ASHG Statement suggests, there are certain questions that must be
answered prior to taking that step.228
Gone are the days of thinking hypothetically about genetic modifications in humans.229 The Frankenstein factor230 has been brought from the
shadows into the limelight. The hype around the evils of genetic editing goes
back to when evil was trying to conduct gene editing based on bigotry.231 The
here and now reality is that editing the human germline is possible, but scientists are incredibly concerned with the ethical implications of such biotechnical advances.232 Some opponents argue that editing the human germline is
like “playing God” and should never be allowed.233 This philosophical argument does not withstand practicality. Modern medicine intervenes on a daily
basis with life-saving surgeries and prescription medicines. “Do not resuscitate” orders are the exception, not the standard.234 The possibility that
CRISPR-Cas9 can be used to treat cancer patients and eradicate debilitating
genetic diseases by modifying the human germline outweighs any abstract
reasoning against the process because, as the ASHG statement proposes, all
clinical applications of this technology must meet stringent standards.235
225. While there are multiple committees in the House and Senate, with each reviewing multiple bills, all those committees must come together to debate, amend, and vote on each
bill. This can be a time-consuming process with many legislators involved. See The Legislative
Process, U.S. HOUSE REPRESENTATIVES, https://www.house.gov/the-house-explained/the-legislative-process [https://perma.cc/3CKF-3CA2].
226. See ASHG Statement, supra note 24.
227. See Glenn McGee, Genetic Imagination: Ethics and 21 Century Genetics, 3 J. L.
& SOC. CHALLENGES 139 (1999) (discussing the history, weaknesses, and proposed reform for
genetic science).
228. See ASHG Statement, supra note 24, at 172-73.
229. See REPRODUCTION & RESPONSIBILITY, supra note 181, at 107.
230. See President’s Commission, supra note 148.
231. See Steven A. Farber, U.S. Scientists’ Role in the Eugenics Movement (19071939): A Contemporary Biologist’s Perspective, 5 ZEBRAFISH 243, 243-44 (2008).
232. See Doudna, supra note 46.
233. See generally GOODFIELD, supra note 135.
234. Codification of this rule varies by state. In Illinois, health care providers are to
provide life-sustaining treatment unless directed otherwise by a do not resuscitate order. 755
ILL. COMP. STAT. 40/65 (2017).
235. ASHG Statement, supra note 24, at 173.
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B. With Great Power Comes Great Responsibility
Ethical issues arise with each new technology.236 The real ethical assessment falls into two categories: (1) issues that arise through human
germline editing success and (2) issues that arise through its failure. A prudent step toward proper regulation of biotechnologies, such as CRISPRCas9, can address all these issues. Regulating this technology now, when the
technology is not yet advanced enough to create viable embryos, could prevent unethical exploration of non-therapeutic use.
Success in experimentation is usually the goal of each scientist conducting an experiment. There is always trial and error, but repetitive successes
are what lead to medical innovations that benefit society as a whole. Even
the “most famous failed experiment[]” contributed to the greater good.237 A
successful germline experiment could take many forms, but opponents of
germline editing focus on the “Frankenstein factor”238 as opposed to the good
that comes from embryonic deletion of the expanded portion of the inheritable gene that causes Huntington’s Disease.239
The benefits of the proposed gene therapy outweigh the possible embryo loss and risks by offering generations without debilitating genetic diseases.240 Eradicating such a devastating inheritable genetic disease, such as
Huntington’s Disease, is a compelling medical rationale that should not be
overlooked. The severity of the condition and lack of other options for treatment meet the standard laid out in the ASHG Statement.241 As CRISPR-Cas9
becomes more widely available, lack of regulation and guidance regarding

236. See, e.g., William S. Singer, Exploring New Terrain: Assisted Reproductive Technology (ART), The Law and Ethics, 8 RUTGERS J. L. & PUB. POL’Y 918 (2010) (discussing the
ethical issues attorneys face when dealing with assisted reproductive technology).
237. The Michelson-Morley experiments focused on the speed of light in a vacuum.
The results of this failed experiment would later support Albert Einstein’s theories of special
relativity. See Sarah Wells, The Most Famous Failed Experiment, STEMVISISONS BLOG (Nov.
15,
2016),
https://ssec.si.edu/stemvisions-blog/most-famous-failed-experiment
[https://perma.cc/QZV9-YEJV].
238. See President’s Commission, supra note 148.
239. What is Huntington’s Disease?, HUNTINGTON’S DISEASE SOC’Y AM.,
http://hdsa.org/what-is-hd/ [https://perma.cc/QD2H-CKEQ] [hereinafter Huntington’s]. Huntington’s Disease, a fatal genetic disorder, is inheritable. “Every child of a parent with HD has
a 50/50 chance of inheriting the expanded gene that causes the disease.” This incurable disease
causes nerve cells in the brain to progressively breakdown until the ability to walk and speak
ceases. See id.
240. See discussion, infra Part IV, Section C.
241. See ASHG Statement, supra note 24, at 173. Suggestions for qualifying rationales
include looking at the quality of life and level of impairment by considering the treatability,
medical severity, available treatments, and the risk of occurrence of the condition. Id.
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this biotechnology promotes unregulated labs to forego proper formal review
and approval before implementing these techniques.242
Opponents of CRISPR-Cas9 modifications point to the high percentage
of off-target mutations that researchers assume are introduced by CRISPRCas9.243 The failure rate of the first non-viable embryo CRISPR-Cas9 experiments in China was astounding.244 Only a fraction of the embryos were successfully modified, leading one stem biologist to say, “Their study should be
a stern warning to any practitioner who thinks the technology is ready for
testing to eradicate disease genes.”245 While these initial studies seem concerning, no new biomedical technology is 100% safe and reliable. Oftentimes, it is a matter of determining if the benefits outweigh the risks. The
need to continue to refine the CRISPR-Cas9 process is part of why scientists
continue to conduct studies on non-viable embryos, just as the ASHG Statement proposes.246 Scientists are not proposing to create designer babies in the
near future.247 Regulating now, with a prohibition on such genetic enhancements, could assuage the ethical concerns of some CRISPR and germline
modification opponents and further the ASHG’s position by requiring a compelling medical rationale with an evidence base.248 Placing limits on the use
of CRISPR-Cas9 will not harm the refinement process, but allows for eventual correction of well-known diseases.
C. Correction of Well-Known Fatal Genetic Diseases
Embracing CRISPR-Cas9 for disease correction only is a step in the
right direction for regulators. Some critics argue that curing deadly genetic
diseases is unnatural because, in the whole of human history, it is normal for
the human population to be reduced by epidemics.249 The benefits of human
germline editing on such diseases outweigh the risks because correcting or
possibly eradicating genetic diseases benefits humanity’s goal of a healthier
human race and can be accomplished by adopting the ASHG suggestions
moving forward. Fatal genetic diseases such as Huntington’s Disease and
242. See id.
243. See Cyranoski & Reardon, supra note 106.
244. Id.
245. Id.
246. ASHG Statement, supra note 24, at 172.
247. See Knoepfler, supra note 14.
248. See id. While Knoepfler calls for a flat-out moratorium on CRISPR use in reproduction, there are consequences to not acting as well. Allowing children to be born with debilitating diseases like Huntington’s, when the technology exists to eradicate it, is irresponsible.
249. See Juan Enriquez, Future Consequences, TED RADIO HOUR (Sept. 14, 2017),
https://www.npr.org/programs/ted-radio-hour/547886174/future-consequences
[https://perma.cc/35W2-KZHC].
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amyotrophic lateral sclerosis (ALS)250 can only benefit from such emerging
biotechnologies as CRISPR-Cas9. Not all fatal inheritable genetic diseases
have high chances to be passed in the familial form.251 While the children of
a parent with Huntington’s Disease have a 50/50 chance of inheriting the
disease,252 only five to ten percent of all ALS cases are inherited from a parent.253 Allowing researchers the freedom and funding to conduct studies
where CRISPR-Cas9 is used to correct or potentially eradicate such devastating diseases at the source, DNA, is the path regulators should take.
This type of germline editing falls under the ASHG suggestion that
“[f]uture clinical application of human germline genome editing should not
proceed unless . . . there is (a) a compelling medical rationale, (b) an evidence
base . . . (c) an ethical justification, and (d) a transparent public process . . .
.”254 The treatment of such diseases is compelling, with an evidence base to
support a clinical use of germline editing, and is compassionate and ethically
sound. Such a framework of requirements prompts scientists to do what is in
the best interest of the patient, while the transparency requirement holds the
researchers accountable to not just the government, but to society.
In addition to the required compelling medical rationale, evidentiary basis, ethical justification, and a transparent public process, enforcement may
be accomplished through an oversight committee. An active committee review for individual projects, similar to the committees formed when in vitro
fertilization was a relatively young technology,255 can be included to ensure
the study falls under the auspices of the framework. Researchers would also
have to comply with the informed consent guidelines as outlined in the Common Rule.256 This Comment leaves medical rationale and ethical

250. ALS is also known as Lou Gehrig’s Disease. This incurable progressive neurological disease affects the neurons “responsible for controlling voluntary muscle movement”
like walking and talking. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet, NAT’L INST.
NEUROLOGICAL DISORDERS & STROKE, https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet
[https://perma.cc/4NY5-ANQF] [hereinafter ALS].
251. For example, sickle cell anemia, a heritable disease that leads to a lower than
normal number of red blood cells, has a one in four chance that a child born to parents who
both carry the sickle cell trait will inherit the condition. Sickle Cell Anemia, NAT’L INSTS.
HEALTH,
https://rarediseases.info.nih.gov/diseases/8614/sickle-cell-anemia
[https://perma.cc/9L5G-U6SW].
252. See Huntington’s, supra note 239.
253. See ALS, supra note 250.
254. See ASHG Statement, supra note 24, at 173.
255. See generally SUZANNE WYMELENBERG & INST. OF MEDICINE, SCIENCE AND
BABIES: PRIVATE DECISION, PUBLIC DILEMMAS 153-56 (1990). Without active oversight and
ethics review committees, the transparency of these technologies lessens and the public mechanism for acknowledging and addressing social and ethical concerns vanishes. Id. at 156.
256. 45 C.F.R. § 46 (2009).
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justifications to the medical community, but goes on to discuss the remaining
issues of transparency and the need for cooperation.
D. Transparency
Transparency is created when public funding is available. Limiting this
biotechnology to private institutions and private funding provides little oversight. As clinical trials move forward, baselines are created for new medications and procedures. It is that new data that provides insight for not only
scientists, but regulators, such as the FDA. As previously discussed, allowing
disease prevention at the source, DNA, has both an evidence base and an
ethical justification.257 Transparency can also be created through publicly
funding such clinical trials because, often to the disdain of researchers, a
great deal of reporting must be done.258
When scientists openly share information in a manner that is accessible
to patients, their families, and other researchers, while respecting the privacy
of the patients, everyone wins.259 There is currently little collaboration in biomedical research, where competition is encouraged and rewarded. 260 It is
often a race to publish instead of a race to alleviate the suffering of those who
depend on biomedical and biotechnical research.261 This needs to change.
Advances in disease identification and treatment should not be withheld from
the masses simply because the federal government cannot move quickly with
enough foresight and confidence in the medical community to properly fund
such research.262 Legislators need to address the lack of proper regulations
and funding by adopting the ASHG’s second suggestion and facilitate research of human germline editing by providing such funds to researchers and
institutions.263 Transparency leads to holding members of the government
and regulatory agencies accountable to the public.264

257. See discussion supra Part IV, Section C.
258. See generally Cures Act, supra note 209.
259. See Sharon Terry, Citizen Science, TED RADIO HOUR (Sept. 28, 2017),
https://www.npr.org/programs/ted-radio-hour/551030943/citizen-science?showDate=201709-29 [https://perma.cc/M25J-MFF5] (discussing researchers’ response to a mother’s plea that
they obtain her children’s blood samples from a team of researchers that had drawn some two
days earlier).
260. Id.
261. Id.
262. See discussion supra Section III, Part B(3)-(6).
263. ASHG Statement, supra note 24, at 173.
264. See Elena Kagan, Presidential Administration, 114 HARV. L. REV. 2245 (2001)
(examining President Clinton’s enhanced presidential control and advocating that this type of
presidential administration creates a more transparent government).
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Federal grants fund much of the research taking place in universities,
hospitals, medical centers, national labs, and other research facilities.265
Drastic cuts have been made to funding allocations from the federal government since fiscal year 2011.266 With the NIH providing the largest amount of
funding for biomedical research, change should originate here.267 While the
Cures Act does provide funding for many areas of biomedical research, the
funding for human germline editing remains woeful.268 It could easily be
classified as precision medicine, but legislators and regulators refuse to do
so. If they were to qualify the CRISPR-Cas9 system as it actually is, a biotechnical advancement capable of precisely editing the human germline in a
manner that benefits families dealing with fatal genetic diseases, and regulate
it, funding could be available. Simply providing funding for the development
of transplantable porcine organs269 could help prevent trade in black market
organs for transplant.270
In addition to lack of funding from NIH, the longevity of funding restraints such as D-W is a concern. The renewal of the appropriations rider
prohibiting funding for human embryos that have been modified at the
germline level is another concern.271 The continuation of such restrictions
should not be condoned simply because it has always been that way.272 Legislators should do what is right for their constituents and the greater good
should take precedent over precedent. The transparency created by the provision of public funding for human germline editing research gives the opportunity for a vocal response from the greatest stakeholders, the American
public.
265. See generally Federal Funding for Biomedical and Related Life Sciences Research: FY 2018, FED’N AM. SOC’YS FOR EXPERIMENTAL BIOLOGY (2017),
http://faseb.org/Portals/2/PDFs/opa/2017/Federal%20Funding%20Report%20FY%202018.pdf [https://perma.cc/4EDJ-AESP].
266. Id. at 1. In the United States, there was a thirteen percent federal funding reduction
for medical research from fiscal year 2011 to fiscal year 2015. In South, East, and Southeast
Asia, funding in this area “grew from 27 to 40 percent.” Id. For the United States to remain
competitive, federal funding should increase and remain stable.
267. See id. at 3. “NIH’s focus on investigator-initiated research identified the underlying causes of many diseases and fostered the translation of scientific discoveries into effective clinical interventions” is just further proof that NIH-funded scientists are essential to furthering research in human germline editing. Id.
268. See funding discussion supra Part II, Section B.
269. See Kolata, supra note 91; see also discussion supra Part I, Section D(2).
270. See Kristin Houser, Black Market Bodies: How Legalizing the Sale of Human
Organs Could Save Lives, FUTURISM (Nov. 6, 2017), https://futurism.com/sale-human-organ/
[https://perma.cc/A7TG-A9DH]. While not advocating for the sale of human organs, transplantable organs produced using CRISPR-Cas9 can serve the same purpose.
271. See Consolidated Appropriations Act of 2017, supra note 206.
272. Legislators may want to remember when their mothers asked, “just because your
friend jumped off a bridge, does that mean you should too?” Keeping up with the status quo
is not a rational reason for denying funding for germline modification research.
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E. International Cooperation
Countries tend to govern as they see fit for their own country.273 That is
a logical and practical way to embrace the needs of the members of its society. Great Britain has decided that genetic editing, within certain boundaries,
serves the greater good.274 If scientists could gather at the International Summit on Human Gene Editing in 2015,275 they can continue to collaborate and
share their successes and failures so that mankind may benefit. The ASHG
Statement is proof that science breaks language barriers and the vast majority
of researchers and scientists have the best interests of society in mind.276
While this Comment does not advocate for all countries to assume the
position of the ASHG, it does address the American legal and scientific landscape. This biotechnology is projected to be worth $25,000,000,000 by 2030
and yet, the American regulatory system has not laid a proper groundwork
for this biotechnology to advance medical research while remaining ethical
and transparent.277 Now is the time for American legislators to address human
germline editing and adopt the ASHG’s position statement in full.
V.

CONCLUSION

It takes time for something new, be it regulatory, political, or scientific, to
become accepted. As the authors of the initial genome sequencing paper
wrote, “[T]he science is only part of the challenge. We must also involve
society at large in the work ahead.”278 Because science moves so quickly,
scientists and regulatory agencies need to consider how best to regulate
germline editing technology such as CRISPR-Cas9 while involving the
273. See, e.g., Jonathan Masters, How Do U.S. Gun Laws Compare to Other Countries?, PBS NEWS HOUR (June 13, 2016, 12:59 PM), https://www.pbs.org/newshour/nation/how-do-u-s-gun-laws-compare-to-other-countries (comparing gun ownership laws in the
United States to those of Canada, where all weapons must be registered; Australia, where
licensing, registration, and firearm safety courses are mandated; and Japan, where most guns
are illegal).
274. See Ewen Callaway, Embryo Editing Gets Green Light, 530 NATURE 18 (2016),
https://www.nature.com/polopoly_fs/1.19270!/menu/main/topColumns/topLeftColumn/pdf/nature.2016.19270.pdf [https://perma.cc/GV6W-QZLD]. CRISPR-Cas9 was approved as a technique to alter genes in human embryos as long as the embryos were destroyed
and non-viable. Id.
275. See SUMMIT, supra note 123.
276. See ASHG Statement, supra note 24.
277. Reenita Das, Gene Editing with CRISPR-Cas9: The Next Step in Human Evolution will be Worth $25 Billion by 2030, FORBES (Dec. 14, 2017, 8:34 AM),
https://www.forbes.com/sites/reenitadas/2017/12/14/gene-editing-with-crispr-cas9-the-nextstep-in-human-evolution-to-be-worth-25-billion-by-2030/#713c12e4449f
[https://perma.cc/HR7S-23YB] (discussing the potential revenues of CRISPR-Cas9 in research, agriculture, human therapeutics, and animal biotech).
278. Initial Sequencing, supra note 28, at 914.
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greatest stakeholders, society. They should do this not only for their constituents, but for all those children who may be born with debilitating or fatal
genetic diseases. They should create regulations for mothers who face only
two choices: sick child or no child. Placing a complete ban on human
germline editing because of what some view as the possible Frankensteinesque outcomes is not only irresponsible but unethical. Change needs to occur and it needs to occur now.

